Abstract:
Designing therapeutic drugs to treat degenerative diseases such as Alzheimer’s and Lou Gehrig’s is challenging enough. But getting them past the protective blood-brain barrier and into brain tissue can prove mind-boggling.Two biotechnology companies that specialize in nanoscale pharmaceuticals signed deals recently that may allow them to accomplish both feats. Advectus Life Sciences Inc. in Vancouver and C Sixty Inc. in Houston announced partnerships that could pave the way for therapies for Alzheimer’s, Lou Gehrig’s disease and other life-threatening conditions.